PREGNANCY, BREAST FEEDING AND FERTILITY PREGNANCY If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Within 10-15 minutes, many clients notice increased alertness, reduced fatigue, or an overall sense of feeling "better." Side effects are rare with proper medical supervision
This is one of the more mechanistically grounded areas of glutathione research, and why hepatic applications come up often in clinical discussions
4.2 Iron overload and dysregulated metabolism Iron overload is a critical factor that drives ferroptosis and worsens ARDS pathology
